UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 304,846 Shares of Moderna, Inc. (NASDAQ:MRNA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 7.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,585,966 shares of the company's stock after selling 304,846 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.93% of Moderna worth $149,104,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Wilmington Savings Fund Society FSB boosted its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna in the 4th quarter valued at about $37,000. Venturi Wealth Management LLC raised its position in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the period. Crowley Wealth Management Inc. bought a new position in Moderna during the 4th quarter worth approximately $41,000. Finally, Itau Unibanco Holding S.A. boosted its stake in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on MRNA shares. Bank of America cut their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. The Goldman Sachs Group downgraded Moderna from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Citigroup assumed coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price on the stock. UBS Group lowered their price target on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Evercore ISI cut their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $53.58.

Moderna Stock Performance

MRNA traded down $0.71 on Wednesday, hitting $26.05. 7,954,323 shares of the company were exchanged, compared to its average volume of 8,035,132. The stock's fifty day moving average is $26.83 and its 200-day moving average is $34.20. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $164.73. The company has a market cap of $10.07 billion, a PE ratio of -2.81 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business's revenue was down 35.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($3.07) EPS. As a group, equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.